Health ProductsNotice to Hospitals

Possible interference of icodextrin, intravenous immunoglobulins, galactose and d-xylose with certain blood glucose meters - Notice to Hospitals

· Published by Health Canada · Official notice

Details

Alert type: Notice to Hospitals
Category: Medical Device
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

Notice about Health Canada advisories

Notice to Hospitals
Health Canada Issued Important Safety Information on Possible interference of icodextrin, intravenous immunoglobulins, galactose and d-xylose with certain blood glucose meters

December 15, 2008

To: Hospital Chief of Medical Staff

Please distribute to the relevant Departments of Nephrology, Emergency Medicine, Internal Medicine, Endocrinology, Pharmacy, Diabetic Education Units and other involved professional staff and post this NOTICE in your institution.

Subject: Possible interference of icodextrin, intravenous immunoglobulins, galactose and d-xylose with certain blood glucose meters

Health Canada would like to bring to your attention the fact that some medical products may interfere with certain types of glucose monitoring systems and therefore may generate falsely elevated blood glucose readingsFootnote 1-4

The test strips of non-glucose-specific glucose meters employ glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose dye oxidoreductase (GDO) enzymatic assays. Both enzymatic assays can react with other sugars such as maltose, galactose and xylose. Therefore, medical products which contain or are metabolised into maltose, galactose and xylose may induce falsely elevated blood glucose readingsFootnote 5-7. These products are used mainly in hospital settings and include, but are not limited to: intravenous immunoglobulin such as hepatitis B immune globulin injection, icodextrin peritoneal dialysis solution, galactose for tolerance test and d-xylose for tolerance test Footnote 8-10.

Glucose-specific monitoring systems employ dehydrogenase-nicotinamide adenine dinucleotide, glucose dehydrogenase flavin adenine dinucleotide, glucose oxidase, or glucose hexokinase enzymatic assays which react only to glucose as substrate. The readings of these systems are not affected in the presence of maltose, galactose and xylose, and therefore, these monitoring systems are not subjected to this notice.

Overestimation of blood glucose levels may result in inappropriate administration of insulin. Iatrogenic insulin induced hypoglycemia/coma and deaths have been reported in diabetics and non-diabetes patients as a result of falsely elevated glucose readings Footnote 11-12. Health Canada has received reports of falsely elevated glucose readings in patients with renal failure and who underwent icodextrin peritoneal dialysis.

In order to prevent falsely elevated glucose readings in healthcare settings associated with use of the non-glucose-specific glucose monitoring systems, Health Canada recommends the following:

  • Identify monitoring systems that are susceptible to interference from sugars such as maltose, galactose and xylose by carefully reading the Instructions for Use, the package insert of the test strips, the box label or by consulting the manufacturer.
  • Using glucose-specific monitoring systems in hospitals.
  • Consider a glucose serum test in situations where the non-glucose-specific glucose meter readings do not coincide with the patient's clinical status.

Health Canada will continue monitoring the issue and provide updates if new safety information becomes available.

Managing marketed health product-related adverse incidents depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse incidents are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious or unexpected adverse incidents in patients using blood glucose monitoring systems or other medical devices should be reported to the marketing authorization holder or to Health Canada at the following address:

Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Telephone: The Inspectorate Hotline 1-800-267-9675

The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada web site.

For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

References

Footnote 1

Gaines AR, Ross Pierce L, Patricia A. Bernhardt. Fatal Iatrogenic Hypoglycemia: Falsely Elevated Blood Glucose Readings with a Point-of-Care Meter Due to a Maltose-Containing Intravenous Immune Globulin Product. http://www.fda.gov/cber/safety/glucfalse.htm

Return to footnote 1 referrer

Footnote 2

Adverse Event Report in FDA-MAUDE: Roche Accu-Chek Comfort Curve Test Strips. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/Detail.cfm?MDRFOI__ID=634797

Return to footnote 2 referrer

Footnote 3

Kroll HR, Maher TR. Significant hypoglycaemia secondary to icodextrin peritoneal dialysate in a diabetic patient. Anesth Analg. 2007; 104:1473-4.

Return to footnote 3 referrer

Footnote 4

Nienhuis WA, Bruijns RH, Vastenburg G, Wouters RS. Hypoglycaemic coma due to falsely elevated glucose values in a patient with diabetes mellitus and peritoneal dialysis. Ned Tijdschr Geneeskd. 2006; 150:1574-6.

Return to footnote 4 referrer

Footnote 5

Riley SG, Chess J, Donovan KL, and Williams JD. Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid. BMJ, 2003; 327:608-9.

Return to footnote 5 referrer

Footnote 6

Wens R, Taminne M, Devriendt J, Collart F, Broeders N, Mestrez F, Germanos H, Dratwa M. A previously undescribed side effect of icodextrin: overestimation of glycemia by glucose analyzer. Perit Dial Int. 1998; 18:603-9.

Return to footnote 6 referrer

Footnote 7

Slim S, Griffiths MJ, Gama R. Icodextrin - still a cause for concern with blood glucose monitoring in continuous ambulatory peritoneal dialysis patients with diabetes. Ann Clin Biochem. 2007; 44:196-7.

Return to footnote 7 referrer

Footnote 8

Octagam Monograph. Octapharma Canada Inc.

Return to footnote 8 referrer

Footnote 9

Cangene Corporation. HepaGamB: Hepatitis B Immune Globulin[Human] Injection with Conditions. http://www.hc-sc.gc.ca/dhpmps/prodpharma/notices-avis/conditions/hepagamb_dhcpl_lapds_089393_e.html

Return to footnote 9 referrer

Footnote 10

Baxter: Extraneal (Icodextrin) Peritoneal Dialysis Solution. www.renalsource.com/extraneal/prescribinginfo.html

Return to footnote 10 referrer

Footnote 11

Kannan S, Rowland CH, Hockings GI, Tauchmann PM. Intragam can interfere with blood glucose monitoring. MJA. 2004; 180(5):251-2. http://www.mja.com.au/public/issues/180_05_010304/letters_010304_fm-3.html

Return to footnote 11 referrer

Footnote 12

Souza SP, Castro MCR, Rodriques RA, Passos RH, Ianhez LE. False hyperglycaemia induced by polyvalent immunoglobulin [letter]. Transplantation. 2005; 80(4):542-3.

Return to footnote 12 referrer

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime